News

New study identifies potential alternatives to Gilead’s Sovaldi

New study identifies potential alternatives to Gilead’s Sovaldi

29-07-2014

There are multiple hepatitis treatments in development that may serve as potential alternatives to Gilead…

AbbVieAntibiotics and Infectious diseasesBristol-Myers SquibbdaclatasvirGilead SciencesGlobalHepatitis C treatmentMarkets & MarketingmericitabinePharmaceuticalRocheSovaldi

EMA advisory unit issues bunch of positive recommendations

EMA advisory unit issues bunch of positive recommendations

22-11-2013

At its late November meetings, the European Medicines Agency’s Committee for Medicinal Products for…

AB ScienceAnti-viralsAntibiotics and Infectious diseasesAstraZenecaBristol-Myers SquibbDeltybaDiabetesEuropeGilead SciencesLucaneLucane PharmaMasicanOncologyOtsukaPharmaceuticalRegulationSovaldiTivicayViiV HealthcareXigduo

Rise in infections means hepatitis C market is expected to peak at $15.5 billion in 2022

27-08-2013

The hepatitis C market is forecast to increase by a massive 230% in the next nine years, according to…

AbbVieAntibiotics and Infectious diseasesBristol-Myers SquibbGilead SciencesGlobalJohnson & JohnsonMarkets & MarketingPharmaceuticalsofosbuvir

MSF calls on pharmaceutical companies to pool HIV drug patents

05-10-2009

The international organization Medecins Sans Frontieres (MSF, or Doctors Without Borders) is calling…

Abbott LaboratoriesAntibiotics and Infectious diseasesBoehringer IngelheimBristol-Myers SquibbGilead SciencesGiliad SciencesGlaxoSmithKlineGlobalGSKMerck KGaAPfizerPharmaceutical

Back to top